Pagaya shares have dipped considerably since the company’s earnings release. Pagaya has long had a trading pattern that is close to indecipherable as well as the remnants of a legacy ownership base who have used liquidity events to sell shares. It remains underfollowed by brokerage analysts. The quarter and the outlook were what they were…
Lots of companies have reported their Q2 results-several hundred in fact. Within our high growth portfolio 4 companies out of 8 scheduled to report this week have now done so. For the most part, the earnings reports emerging range from good to excellent. Q2 is shaping up to have been a better quarter for software…
Sale of 150 shares of CyberArk (Entire Position); Purchase of 200 shares of Pagaya; Purchase of 200 shares of Rubrik; Purchase of 250 shares of Samsara; Purchase of 200 shares of Dynatrace; Purchase of 200 shares of Braze; Purchase of 50 shares of Atlassian; Purchase of 20 shares of Monday We have made some changes…
High growth equities were under some pressure in trading Thursday morning. Overall, the high growth portfolio has fallen about 3%. There is still tariff angst as the president has sent aggressive letters to some trade partners such as Brazil threatening punitive tariffs because of political issues. Further, the QQQs and other indices made all-time highs…
Shares of Rubrik spiked a little this morning and I got off a sale of 300 shares at my limit of $96.99. I had tried for more, but this was the best price at which I got a fill. Investors-or dare I say traders have been very picky with how they react to earnings. Shares of both…
Summary Dynatrace is one of the clear leaders in the observability space, driven by differentiated AI technology (Davis) and a robust platform approach (Grail, DPS). Despite macroeconomic uncertainties, Dynatrace’s prudent guidance, strong pipeline growth, and expanding enterprise focus position it for revenue acceleration beyond current forecasts. The company’s simple, transparent pricing and successful channel strategy—especially…
AS we had discussed in this week’s commentary, we believed that the recent appreciation of IT stocks had taken some of the positions in the portfolio to valuations that were a bit stressed. Today, that opinion was seconded by the analyst team at Raymond James with regards to Nutanix. That precipitated our sale of a…
Sale of 150 shares of Dynatrace (remaining position); Purchase of 30 shares of Datadog; Purchase of 150 shares of Nutanix. Dynatrace: We eliminated the last of our Dynatrace (DT) position this morning. We were sorry to have to eliminate the position, but at this point the growth divergence between Dynatrace and Datadog was just too great to…
Sales of 1500 shares of UiPath and Sale of 150 shares of Dynatrace: Purchase of 300 shares of Nutanix, Purchase of 200 shares of GitLab As we had indicated, we have now eliminated UiPath from the portfolio. Its latest earnings report and guidance were very disappointing, and while the narrative may play out, we simply…
Sale of 100 Dynatrace and purchase of 200 shares of Confluent The market continues in a risk off pattern this Monday morning. Many stocks are still reacting to the perceived read-through from the results of MongoDB. As I tried to suggest, Mongo’s issues are grossly exaggerated, and really are not representative of what is actually…